Using the TyG index to detect early microvascular blockage after emergency PCI for heart attack
Triglyceride Glucol Index for Predicting the Value of No-Reflow in Patients Undergoing Emergency PCI for Acute Myocardial Infarction
This project will test whether the TyG (triglyceride-glucose) index can help doctors spot early small-vessel blockage (microvascular obstruction) in people treated with emergency PCI for a heart attack.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Third Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan Province,China) |
| Trial ID | NCT07042321 on ClinicalTrials.gov |
What this trial studies
This prospective cohort will enroll about 300 patients with acute myocardial infarction treated with emergency percutaneous coronary intervention at the Third Xiangya Hospital between June 2024 and August 2025. Participants will have cardiac magnetic resonance imaging 3–7 days after PCI and collection of demographic data, clinical history, coronary angiography findings, laboratory metabolic markers (including blood glucose and lipids), IVUS plaque characteristics, and CMR results. The cohort will be stratified by TyG index level to examine the relationship between TyG and presence of early microvascular obstruction and to compare in-hospital cardiovascular adverse events across TyG groups. Analyses will test associations between baseline TyG values and MVO on CMR while controlling for relevant confounders.
Who should consider this trial
Good fit: Adults (≥18 years) presenting with STEMI within guideline time windows or very high‑risk NSTEMI who undergo emergency PCI and can receive CMR 3–7 days after the procedure and provide informed consent.
Not a fit: Patients with non-obstructive MI, severe chronic kidney disease (eGFR <20 mL/min/1.73 m²), failed emergency PCI, pregnancy, or those unable to obtain clear CMR images are excluded and unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, the TyG index could provide a simple early marker to identify heart attack patients at higher risk of microvascular obstruction so clinicians can tailor monitoring and treatment.
How similar studies have performed: Prior observational work has linked the TyG index and other metabolic markers to cardiovascular risk, but applying TyG specifically for early detection of MVO after emergency PCI is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * STEMI symptom onset time \< 12 hours. * STEMI symptom onset time 12-48 hours, with ongoing ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias. * Very high-risk NSTEMI; undergoing emergency PCI treatment. * Voluntary signed informed consent form. Exclusion Criteria: * Non-obstructive acute myocardial infarction. * Severe chronic kidney disease (defined as estimated glomerular filtration rate \<20 mL/min per 1.73 m²). * Pregnant women or those planning to become pregnant. * Failure of emergency PCI. * Unclear CMR images
Where this trial is running
Changsha, Hunan Province,China
- Xiangya Third Hospital of Central South University — Changsha, Hunan Province,China, China (Recruiting)
Study contacts
- Study coordinator: can Zhu Can
- Email: zhucan1021@163.com
- Phone: +8613348674820
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.